RecruitingPhase 3NCT05905172
Hydronidone Capsules in Long-term Treatment in Patients With Chronic Viral Hepatitis B Liver Fibrosis
Studying NLRP3-associated autoinflammatory disease
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Beijing Continent Pharmaceutical Co, Ltd.
- Principal Investigator
- Lungen Lu, DrShanghai General Hospital, Shanghai Jiao Tong University School of Medicine
- Intervention
- Hydronidone capsules(drug)
- Enrollment
- 248 target
- Eligibility
- 18-65 years · All sexes
- Timeline
- 2023 – 2028
Study locations (23)
- Beijing Ditan Hospital Capital Medical University, Beijing, Beijing Municipality, China
- Shanghai General Hospital,Shanghai Jiao Tong University, Shanghai, Shanghai Municipality, China
- Beijing youan hospital, the capital of the capital, Beijing, China
- Tsinghua Changgeng Hospital, Beijing, Beijing, China
- The First Affiliated Hospital of Bengbu Medical University, Bengbu, China
- The Second Xiangya Hospital, Central South University, Changsha, China
- Xiangya Hospital, Central South University, Changsha, China
- The First Affiliated Hospital of Chongqing Medical University, Chongqing, China
- Three Gorges Hospital affiliated to Chongqing University, Chongqing, China
- Guizhou Provincial People's Hospital, Guizhou, China
- Hangzhou Xixi Hospital (Hangzhou Sixth People's Hospital), Hangzhou, China
- Henan Provincial People's Hospital, Henan, China
- Affiliated Hospital of Traditional Chinese Medicine of Southwest Medical University, Luzhou, China
- Nanchang Ninth Hospital (Nanchang Central Hospital), Nanchang, China
- The First Affiliated Hospital of Nanchang University, Nanchang, China
- +8 more locations on ClinicalTrials.gov
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT05905172 on ClinicalTrials.govOther trials for NLRP3-associated autoinflammatory disease
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE1, PHASE2NCT07540338A Study to Investigate Lithium Brain/Plasma Pharmacokinetics and Safety of an AL001 Oral Capsule Compared to a Marketed Immediate-release Lithium Carbonate Capsule in Subjects With Bipolar I DisorderAlzamend Neuro, Inc.
- RECRUITINGPHASE3NCT07343778A Clinical Trial Evaluating the Safety of Hydronidone Capsules in Patients With Hepatic Fibrosis and Liver CirrhosisBeijing Continent Pharmaceutical Co, Ltd.
- RECRUITINGPHASE2NCT07364448A Study to Evaluate the Safety of Hydronidone Capsules in Patients With Liver FibrosisBeijing Continent Pharmaceutical Co, Ltd.
- RECRUITINGNANCT06544018Circadian Rhythm Deregulation in Patients With CAPSHospices Civils de Lyon
- RECRUITINGNANCT07203963Additional Effects of Niel-asher Technique on Patients With Adhesive CapsulitisRiphah International University
- RECRUITINGPHASE1NCT07532135Safety of Mulberry Leaf Extract Capsule on Blood Glucose Control in Healthy VolunteerChulalongkorn University
- RECRUITINGPHASE4NCT07114120Clinical Study on the Treatment of Stable Bronchiectasis With Bailing Capsules Combined With Guben Kechuan GranulesSecond Affiliated Hospital, School of Medicine, Zhejiang University
- RECRUITINGPHASE3NCT06930794A Study of Vebreltinib and Platinum-Containing Double Agents in Subjects With MET-PositiveBeijing Pearl Biotechnology Limited Liability Company
See all trials for NLRP3-associated autoinflammatory disease →